Richard Saynor - Novartis Chief Sandoz

All Insiders . USA . 
Stock . Novartis AG . Stakeholders . Insider . Richard Saynor
NVSEF Stock  USD 116.60  8.74  8.10%   

Insider

Richard Saynor is Chief Sandoz of Novartis AG
Age 56
Phone41 61 324 1111
Webhttps://www.novartis.com

Novartis Management Efficiency

The company has return on total asset (ROA) of 0.0645 % which means that it generated a profit of $0.0645 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.1093 %, meaning that it generated $0.1093 on every $100 dollars invested by stockholders. Novartis' management efficiency ratios could be used to measure how well Novartis manages its routine affairs as well as how well it operates its assets and liabilities.
Novartis AG has accumulated 20.24 B in total debt with debt to equity ratio (D/E) of 0.47, which is about average as compared to similar companies. Novartis AG has a current ratio of 1.28, suggesting that it may not be capable to disburse its financial obligations in time and when they become due. Debt can assist Novartis until it has trouble settling it off, either with new capital or with free cash flow. So, Novartis' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Novartis AG sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Novartis to invest in growth at high rates of return. When we think about Novartis' use of debt, we should always consider it together with cash and equity.

Similar Executives

Showing other executives

INSIDER Age

Patrice BulaNovartis AG ADR
65
Samir MDNovartis AG ADR
62
Josep CatllaSanofi ADR
N/A
Claudia BockstiegelRoche Holding AG
59
Johannes MDRoche Holding AG
66
Aradhana MDAstraZeneca PLC
48
Barbara SchadlerRoche Holding AG
61
Naoki BScAstellas Pharma
N/A
Rodrigo SantosBayer AG
50
Collette TaylorAstellas Pharma
60
Tony WoodGlaxoSmithKline PLC ADR
N/A
Stig OgataAstellas Pharma
N/A
Bruno EschliRoche Holding Ltd
N/A
Suketu DesaiScilex Holding
59
MBA DVMAstraZeneca PLC
64
Gabriel HarnierBayer AG
52
Minoru KikuokaAstellas Pharma
N/A
Johannes MDRoche Holding AG
66
Anne BealGlaxoSmithKline PLC ADR
58
Thomas SchineckerRoche Holding Ltd
48
Catherine LevittAstellas Pharma
N/A
Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company was incorporated in 1996 and is headquartered in Basel, Switzerland. Novartis operates under Drug ManufacturersGeneral classification in the United States and is traded on OTC Exchange. It employs 104323 people. Novartis AG [NVSEF] is a Pink Sheet which is traded between brokers as part of OTC trading.

Management Performance

Return On Equity0.11
Return On Asset0.0645

Novartis AG Leadership Team

Elected by the shareholders, the Novartis' board of directors comprises two types of representatives: Novartis inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Novartis. The board's role is to monitor Novartis' management team and ensure that shareholders' interests are well served. Novartis' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Novartis' outside directors are responsible for providing unbiased perspectives on the board's policies.
Richard Saynor, Chief Sandoz
Steffen Lang, Global Head of Novartis Technical Operations, Member of the Executive Committee
MarieFrance Tschudin, Pres Officer
Paul Penepent, Head Accounting
Samir MD, Global Relations
Robert PharmD, Chief Officer
Klaus Moosmayer, Chief Ethics Risk and Compliance Officer, Member of the Executive Committee
Karen Hale, Chief Officer
Vasant Narasimhan, Global Head of Drug Development and Chief Medical Officer for Novartis, Member of the Executive Committee
Harry Kirsch, Chief Officer

Novartis Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Novartis a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Return On Equity0.11
Return On Asset0.0645
Profit Margin0.13 %
Operating Margin0.25 %
Current Valuation207.39 B
Shares Outstanding2.12 B
Shares Owned By Insiders3.74 %
Shares Owned By Institutions33.74 %
Price To Earning25.00 X
Price To Book3.22 X

Currently Active Assets on Macroaxis

ZLABZai Lab
ASLEAerSale Corp
ATSAT S Austria
HMYHarmony Gold Mining
FSMFortuna Silver Mines

Other Information on Investing in Novartis Pink Sheet

Novartis financial ratios help investors to determine whether Novartis Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Novartis with respect to the benefits of owning Novartis security.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY